CoChat

Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review

Open access
Nuzbrokh, Yan, Kassotis, Alexis S., Ragi, Sara D., Jauregui, Ruben, Tsang, Stephen H. · 2020 · Ophthalmology and Therapy
Cited by 29

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Patient safety is a primary priority in the conduction of retinal gene therapy trials. An understanding of risk factors and mitigation strategies for post-procedure complications is crucial for the optimization of gene therapy clinical trial protocols. In this review, we synthesize the literature on ocular delivery methods, vector platforms, and treatment-emergent adverse effects in recent gene therapy clinical trials for inherited retinal diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40123-020-00287-1

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 88

  1. Ong T, Pennesi ME, Birch DG, et al. Adeno-associated viral gene therapy for inherited retinal disease. Pharm Res. 2019;36:34. · DOI
  2. Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci. 2011;52:3051–9. · DOI · Paper page
  3. Kelley RA, Conley SM, Makkia R, et al. DNA nanoparticles are safe and nontoxic in non-human primate eyes. Int J Nanomed. 2018;13:1361–79. · DOI · Paper page
  4. Neffendorf JE, Gupta B, Williamson TH. Intraoperative complications of patients undergoing small-gauge and 20-gauge vitrectomy: a database study of 4,274 procedures. Eur J Ophthalmol. 2017;27:226–30. · doi:10.5301/ejo.5000856
  5. Mentens R, Stalmans P. Comparison of postoperative comfort in 20 gauge versus 23 gauge pars plana vitrectomy. Bull Soc Belge Ophtalmol. 2009;311:5–10.
  6. Kellner L, Wimpissinger B, Stolba U, et al. 25-gauge vs 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial. Br J Ophthalmol. 2007;91:945–8. · doi:10.1136/bjo.2006.106799
  7. Inoue Y, Kadonosono K, Yamakawa T, et al. Surgically-induced inflammation with 20-, 23-, and 25-gauge vitrectomy systems: an experimental study. Retina. 2009;29:477–80. · doi:10.1097/iae.0b013e31819a6004
  8. Nam Y, Chung H, Lee JY, et al. Comparison of 25- and 23-gauge sutureless microincision vitrectomy surgery in the treatment of various vitreoretinal diseases. Eye. 2010;24:869–74. · doi:10.1038/eye.2009.206
  9. Veritti D, Sarao V, Lanzetta P. A propensity-score matching comparison between 27-gauge and 25-gauge vitrectomy systems for the repair of primary rhegmatogenous retinal detachment. J Ophthalmol. 2019;2019:3120960. · DOI
  10. Igelman AD, Johnson JA, Taylor SC, et al. Postoperative complication rates in 23- vs 25-gauge pars plana vitrectomy. J VitreoRetin Dis. 2018;2:272–5. · doi:10.1177/2474126418785824
  11. Ho LY, Garretson BR, Ranchod TM, et al. Study of intraocular pressure after 23-gauge and 25-gauge pars plana vitrectomy randomized to fluid versus air fill. Retina. 2011;31:1109–17. · doi:10.1097/iae.0b013e31820b5b9b
  12. Charles S, Ho AC, Dugel PU, et al. Clinical comparison of 27-gauge and 23-gauge instruments on the outcomes of pars plana vitrectomy surgery for the treatment of vitreoretinal diseases. Curr Opin Ophthalmol. 2020;31:185–91. · doi:10.1097/icu.0000000000000659
  13. Ochakovski GA, Bartz-Schmidt KU, Fischer MD. Retinal gene therapy: surgical vector delivery in the translation to clinical trials. Front Neurosci. 2017;11:174. · DOI · Paper page
  14. Fan KC, Yannuzzi NA, Patel NA, et al. Surgical techniques for the subretinal delivery of pediatric gene therapy. Ophthalmol Retina. 2020;4:644–5. · DOI
  15. Shields RA, Ludwig CA, Powers MA, et al. Postoperative adverse events, interventions, and the utility of routine follow-up after 23-, 25-, and 27-gauge pars plana vitrectomy. Asia-Pac J Ophthalmol. 2019;8:36–42.
  16. Alexander P, Michaels L, Newsom R. Is day-1 postoperative review necessary after pars plana vitrectomy? Eye (London, England). 2015;29:1489–94. · doi:10.1038/eye.2015.134
  17. Ahn SJ, Woo SJ, Ahn J, et al. Comparison of postoperative intraocular pressure changes between 23-gauge transconjunctival sutureless vitrectomy and conventional 20-gauge vitrectomy. Eye. 2012;26:796–802. · doi:10.1038/eye.2012.23
  18. Kwon HJ, Kwon OW, Song WK. Semiautomated subretinal fluid injection method using viscous fluid injection mode. Retina. 2019;39:S174–S176176. · DOI
  19. Park JC, Ramasamy B, Shaw S, et al. A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy: incidence and risk factors. Br J Ophthalmol. 2014;98:529. · DOI
  20. Bhende M, Raman R, Singh N, et al. Risk factors for endophthalmitis after pars plana vitrectomies in a Tertiary Eye Institute in India. Ophthalmol Retina. 2018;2:779–84. · doi:10.1016/j.oret.2018.01.001
  21. Gupta OP, Maguire JI, Eagle RC Jr, et al. The competency of pars plana vitrectomy incisions: a comparative histologic and spectrophotometric analysis. Am J Ophthalmol. 2009;147(243–50):e1.
  22. Reibaldi M, Longo A, Reibaldi A, et al. Diathermy of leaking sclerotomies after 23-gauge transconjunctival pars plana vitrectomy: a prospective study. Retina. 2013;33:939–45. · doi:10.1097/iae.0b013e3182725d65
  23. Arana LA, Moreira ATR, Grandinetti AA, et al. Novel vicryl releasable suture technique to close leaking sclerotomies in a transconjunctival vitrectomy. Retina. 2019;39(Suppl 1):S108–S111111. · doi:10.1097/iae.0000000000002115
  24. Felfeli T, Altomare F, Mandelcorn ED. Sutureless closure of 23-and 25-gauge leaking sclerotomies with the scleral needling technique. Retina. 2020;40:838–44. · DOI
  25. Shimada H, Nakashizuka H, Hattori T, et al. Reduction of vitreous contamination rate after 25-gauge vitrectomy by surface irrigation with 0.25% povidone–iodine. Retina. 2013;33:143–51. · doi:10.1097/iae.0b013e318261a6ce
  26. Yamane S, Kadonosono K, Inoue M, et al. Effect of intravitreal gas tamponade for sutureless vitrectomy wounds: three-dimensional corneal and anterior segment optical coherence tomography study. Retina. 2011;31:702–6. · doi:10.1097/iae.0b013e3181f0d2e6
  27. Chiang A, Kaiser RS, Avery RL, et al. Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes. Retina. 2011;31:1513–7. · DOI
  28. Chandra A, Xing W, Kadhim MR, et al. Suprachoroidal hemorrhage in pars plana vitrectomy: risk factors and outcomes over 10 years. Ophthalmology. 2014;121:311–7. · doi:10.1016/j.ophtha.2013.06.021
  29. Woo SJ, Park KH, Hwang J-M, et al. Risk factors associated with sclerotomy leakage and postoperative hypotony after 23-gauge transconjunctival sutureless vitrectomy. Retina. 2009;29:456–63. · DOI
  30. Mimouni M, Abualhasan H, Derman L, et al. Incidence and risk factors for hypotony after 25-gauge pars plana vitrectomy with nonexpansile endotamponade. Retina. 2020;40:41–6. · DOI
  31. Shimozono M, Oishi A, Kimakura H, et al. Three-step incision for 23-gauge vitrectomy reduces postoperative hypotony compared with an oblique incision. Ophthalmic Surg Lasers Imaging. 2011;42:20–5. · doi:10.3928/15428877-20101025-02
  32. Inoue M, Shinoda K, Shinoda H, et al. Two-step oblique incision during 25-gauge vitrectomy reduces incidence of postoperative hypotony. Clin Exp Ophthalmol. 2007;35:693–6. · doi:10.1111/j.1442-9071.2007.01580.x
  33. Barak Y, Heroman JW, Schaal S. Use of 25% sulfur hexafluoride gas mixture may minimize short-term postoperative hypotony in sutureless 25-gauge pars plana vitrectomy surgery. Clin Ophthalmol (Auckland, NZ). 2013;7:423–6.
  34. Ehlers JP, Dupps WJ, Kaiser PK, et al. The Prospective Intraoperative and Perioperative Ophthalmic ImagiNg with Optical CoherEncE TomogRaphy (PIONEER) study: 2-year results. Am J Ophthalmol. 2014;158:999–1007. · DOI · Paper page
  35. Roizenblatt M, Edwards TL, Gehlbach PL. Robot-assisted vitreoretinal surgery: current perspectives. Robot Surg (Auckland). 2018;5:1–11.
  36. Igarashi T, Miyake K, Asakawa N, et al. Direct comparison of administration routes for AAV8-mediated ocular gene therapy. Curr Eye Res. 2013;38:569–77. · DOI · Paper page
  37. Gamlin PD, Alexander JJ, Boye SL, et al. SubILM injection of AAV for gene delivery to the retina. Methods Mol Biol (Clifton, NJ). 2019;1950:249–62. · DOI · Paper page
  38. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–83. · DOI · Paper page
  39. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1–S18. · DOI · Paper page
  40. Patel SN, Gangaputra S, Sternberg P Jr, et al. Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol. 2020;65:408–20. · DOI
  41. Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45:143–9. · DOI · Paper page
  42. Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;2018:8567912. · DOI
  43. Wen JC, McCannel CA, Mochon AB, et al. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129:1551–4. · DOI
  44. Storey P, Dollin M, Pitcher J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121:283–9. · DOI · Paper page
  45. Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29:19–32. · DOI
  46. Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33:1968–70. · DOI
  47. Munro M, Williams GR, Ells A, et al. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. Br J Ophthalmol. 2018;102:1254–8. · DOI
  48. Tustin A, Kim SJ, Chomsky A, et al. Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection. Retina. 2014;34:935–42. · doi:10.1097/iae.0000000000000014
  49. Storey PP, Tauqeer Z, Yonekawa Y, et al. The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol. 2019;199:200–8. · DOI
  50. Levinson JD, Garfinkel RA, Berinstein DM, et al. Timing of povidone-iodine application to reduce the risk of endophthalmitis after intravitreal injections. Ophthalmol Retina. 2018;2:654–8. · DOI
  51. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676–98. · DOI · Paper page
  52. Karabag RY, Parlak M, Cetin G, et al. Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. Dig J Ophthalmol. 2015;21:8. · doi:10.5693/djo.02.2013.09.005
  53. Knecht PB, Michels S, Sturm V, et al. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina (Philadelphia, Pa). 2009;29:1175–81. · DOI
  54. Storey PP, Pancholy M, Wibbelsman TD, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmology. 2019;126:1424–31. · DOI
  55. Yun C, Oh J, Hwang SY, et al. Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 2015;253:1465–70. · DOI
  56. Lemos V, Cabugueira A, Noronha M, et al. Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. Ophthalmologica. 2015;233:162–8. · DOI
  57. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128:1523–7. · DOI
  58. Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158(319–27):e2.
  59. Pang CE, Mrejen S, Hoang QV, et al. Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina. 2015;35:1401–6. · DOI
  60. Gomez J, Koozekanani DD, Feng AZ, et al. Strategies for improving patient comfort during intravitreal injections: results from a survey-based study. Ophthalmol Ther. 2016;5:183–90. · DOI
  61. Chen X, Seth RK, Rao VS, et al. Effects of music therapy on intravitreal injections: a randomized clinical trial. J Ocul Pharmacol Ther. 2012;28:414–9. · DOI
  62. Shiroma HF, Takaschima AKK, Farah ME, et al. Patient pain during intravitreal injections under topical anesthesia: a systematic review. Int J Retina Vitreous. 2017;3:23. · DOI
  63. Karimi S, Mosavi SA, Jadidi K, et al. Which quadrant is less painful for intravitreal injection? A prospective study. Eye. 2019;33:304–12. · DOI
  64. Popovic MM, Muni RH, Nichani P, et al. Topical nonsteroidal anti-inflammatory drugs for pain resulting from intravitreal injections: a meta-analysis. Ophthalmol Retina. 2020;4:461–70. · DOI
  65. Li Q, Miller R, Han P-Y, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–9.
  66. Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53:4433–41. · DOI · Paper page
  67. Yiu G, Chung SH, Mollhoff IN, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev. 2020;16:179–91. · DOI · Paper page
  68. Yeh S, Kurup SK, Wang RC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). RETINA. 2019;39:1880–8. · DOI · Paper page
  69. Boye SE, Alexander JJ, Witherspoon CD, et al. Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gene Ther. 2016;27:580–97. · DOI · Paper page
  70. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60. · DOI · Paper page
  71. Pennesi ME, Weleber RG, Yang P, et al. Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Hum Gene Ther. 2018;29:1428–37. · DOI · Paper page
  72. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology. 2013;120:1283–91. · DOI · Paper page
  73. Wang X, Yu C, Tzekov RT, et al. The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:49. · DOI · Paper page
  74. Dimopoulos IS, Hoang SC, Radziwon A, et al. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am J Ophthalmol. 2018;193:130–42. · DOI · Paper page
  75. MacDonald IM, Moen C, Duncan JL, et al. Perspectives on gene therapy: choroideremia represents a challenging model for the treatment of other inherited retinal degenerations. Transl Vis Sci Technol. 2020;9:17. · DOI · Paper page
  76. Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110:1151–8. · DOI · Paper page
  77. Sun D, Schur RM, Sears AE, et al. Non-viral gene therapy for Stargardt disease with ECO/pRHO-ABCA4 self-assembled nanoparticles. Mol Ther. 2020;28:293–303. · DOI · Paper page
  78. Wilson DJ, Sahel JA, Weleber RG, et al. One year results of a phase I/IIa study of SAR422459 in patients with Stargardt macular degeneration (SMD). Investig Ophthalmol Vis Sci. 2017;58:3385.
  79. Talib M, van Schooneveld MJ, Thiadens AA, et al. Clinical and genetic characteristics of male patients with rpgr-associated retinal dystrophies: a long-term follow-up study. Retina. 2019;39:1186–99. · DOI · Paper page
  80. Wu Z, Hiriyanna S, Qian H, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet. 2015;24:3956–70. · DOI · Paper page
  81. Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26:354–9. · DOI · Paper page
  82. Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. Br J Ophthalmol. 2004;88:291–7. · DOI · Paper page
  83. Hirji N, Aboshiha J, Georgiou M, et al. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet. 2018;39:149–57. · DOI · Paper page
  84. Yu-Wai-Man P, Griffiths PG, Brown DT, et al. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72:333–9. · DOI · Paper page
  85. Yuan J, Zhang Y, Liu H, et al. Seven-year follow-up of gene therapy for leber’s hereditary optic neuropathy. Ophthalmology. 2020;127:1125–7. · DOI · Paper page
  86. Pimenides D, George ND, Yates JR, et al. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005;42:e35. · DOI
  87. Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retinal eye Res. 2012;31:195–21212. · DOI · Paper page
  88. Vijayasarathy C, Sui R, Zeng Y, et al. Molecular mechanisms leading to null-protein product from retinoschisin (RS1) signal-sequence mutants in X-linked retinoschisis (XLRS) disease. Hum Mutat. 2010;31:1251–60. · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H.
Venue
Ophthalmology and Therapy
Published
2020-08-01
Volume
9
Issue
4
Pages
709-724
ISSN
  • 2193-6528 (ISSN-L)
  • 2193-8245
OpenAlex
W3046752007
Cited by
29
References
36
FWCI
0.39
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Foundation Fighting Blindness (TA-NMT-0116-0692- COLU)
  • Foundation for the National Institutes of Health (P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437)
  • New York State (SDHDOH01-C32590GG-3450000)
  • Research to Prevent Blindness
  • National Cancer Institute Core (5P30CA013696)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. https://app.cochat.ai/papers/10.1007/s40123-020-00287-1
The paper
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020). Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-020-00287-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.